Skip to main content
. Author manuscript; available in PMC: 2019 Nov 5.
Published in final edited form as: Mol Pharm. 2018 Sep 28;15(11):5162–5173. doi: 10.1021/acs.molpharmaceut.8b00717

Fig. 8.

Fig. 8.

The percentages of immune cells in tumor tissues were analyzed by flow cytometry. 4T1.2 tumor bearing mice were received various treatments of Taxol, PEG5K-Fmoc-NLG2, PTX/PEG5K-Fmoc-NLG2 mixed micelles, Sun/PEG5K-Fmoc-NLG2 mixed micelles or PTX+Sun/PEG5K-Fmoc-NLG2 mixed micelles at a PTX dosage of 10 mg/kg and SUN dosage of 10 mg/kg for 3 times at every 3 days and tumoral T-cell infiltration, including (A) CD4+ and CD8+, (B) IFN-γ+CD4+ T cells, (C) IFN-γ+CD8+ T cells and (D) granzyme B-positive CD8+ T cells, were measured by flow cytometry. (E) Gr-1highCD11b+ granulocytic (G-MDSC) and Gr-1intCD11b+ monocytic (M-MDSC) were analyzed by flow cytometry. *P < 0.05.